TARPEYO was approved in December 2021.
TARPEYO is a prescription medicine used to reduce levels of protein in the urine (proteinuria) in adults with a kidney disease called primary immunoglobulin A nephropathy (IgAN) who are at high risk of disease progression. It is not known if TARPEYO is safe and effective in children.
This approval is based on a reduction in proteinuria. Confirmatory clinical trial results are needed to verify the clinical benefit of slowing kidney function decline
The TARPEYO Patient Brochure provides helpful information about TARPEYO. Click here to download this brochure.
FREQUENTLY ASKED QUESTIONS
WHAT IS TARPEYO?
TARPEYO is a prescription medicine used to reduce levels of protein in the urine (proteinuria) in adults with IgA Nephropathy who are at high risk of disease progression. TARPEYO was specifically designed for IgA Nephropathy.
WHEN WAS TARPEYO APPROVED?
TARPEYO was FDA-approved in December 2021 and is available by prescription. This approval is based on reduction in proteinuria. Confirmatory clinical trial results are needed to verify the clinical benefit of slowing kidney function decline.
HOW IS TARPEYO THOUGHT TO WORK?
TARPEYO is designed to deliver treatment to an area of the gut thought to play a role in IgA Nephropathy. Types of cells in the gut are thought to be responsible for the production of IgA1. These types of IgA1 can build up in the kidneys and cause IgA Nephropathy. TARPEYO can reduce the amount of this antibody.*
*It has not been established to what extent the efficacy of TARPEYO is from local effects (in the gut) vs systemic effects (in circulation).
HOW IS TARPEYO DIFFERENT FROM OTHER STEROIDS I’VE BEEN PRESCRIBED FOR IgA NEPHROPATHY?
TARPEYO is the first FDA-approved treatment to reduce protein levels in the urine of patients with IgA Nephropathy and was designed for delivery to the area where the disease is thought to come from. Other steroids have not established efficacy or safety and are not FDA approved for IgA Nephropathy.